Back to search results

Observational Study for KRAS G12R Pancreatic Cancer with MEK Inhibitor Therapies

This observational study is looking at how well different treatments work for advanced pancreatic cancer that has a specific change in the KRAS gene called G12R. You might be eligible if you are 18 or older and have this type of pancreatic cancer. The study is comparing different combinations of treatments, including those with a MEK inhibitor (MEKi), MEKi-HCQ, MEKi-EGFRi, or other combination therapies without MEKi. Researchers will look at your medical records to see if your cancer has not grown or spread after 6 months of treatment. The study plans to include 80 participants, but its current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will collect and analyze existing medical data. It plans to enroll 80 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 6 months, focusing on whether the cancer has not progressed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05630989

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Recruiting
Not specifiedAges 18+Observational
Mandana Kamgar, MD
~80 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:combination therapy with no MEKicombination therapy with MEKi-HCQcombination therapy with MEKi-EGFRicombination therapy with MEKi.

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The number of subjects with no progression.
Measured over 6 months

Conditions

Pancreatic Ductal Adenocarcinoma

Explore related trials

Pancreatic Ductal AdenocarcinomaGTPase KRas

NCT05630989

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsinstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Mandana Kamgar, MD, MPH · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin

Who to contact

Mandana Kamgar, MD, MPH
[email protected]
414-805-4600
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • The number of subjects with no progression.6 months

    This is defined as the time from the start of treatment until six months on treatment, or disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death, whichever occurs first.